| Business Update
Published Wed, Sep 4 2024 11:47 AM UTC
In a significant step forward in the treatment of diabetic macular edema (DME), Merck (NYSE: MRK), known as MSD outside the United States and Canada, and its wholly-owned subsidiary EyeBio have announced the initiation of the Phase 2b/3 BRUNELLO clinical trial for Restoret (MK-3000, formerly EYE103). This investigational therapy represents a novel approach in the management ...
|
| Business Update
Published Thu, Aug 29 2024 11:47 AM UTC
'Merck Discontinues KEYTRUDA Phase 3 Trial Amidst New Developments'In the realm of pharmaceutical endeavors, the esteemed enterprise Merck, known as MSD beyond the borders of the United States and Canada, has furnished the public with significant updates regarding their Phase 3 trials, specifically KEYNOTE-867 and KEYNOTE-630. The disclosure, made from their headquarters in ...
|
| Business Update
Published Fri, Aug 9 2024 12:57 PM UTC
'''' The pharmaceutical landscape is a dynamic and competitive arena where strategic acquisitions and collaborations can substantially shape a company?s portfolio. Merck & Co., Inc. (known as MSD outside the United States and Canada) has made significant strides in diversifying its therapeutic offerings through the acquisition of novel investigational therapies. This articl...
|
| Merck And Co Inc
As the financial landscape shifts, Merck & Co Inc has demonstrated remarkable resilience and growth, emerging as a beacon of stability within the pharmaceutical sector. For the quarter ending June 30, 2024, the company reported a revenue surge of 7.163% year-on-year, reaching an impressive $16.11 billion. This robust performance has enabled the pharmaceutical giant to reclaim profitability, achieving earnings per share of $2.14?an encouraging sign for investors and stakeholders alike.
In comparison to the previous quarter, Merck's revenue increased by 2.136% from $15.78 billion, while earnings per share saw a significant jump of 14.44%, up from $1.87 per share. This upward trajectory underscores the company?s strategic initiatives and commitment to innovation.
|
| Stocks on the Move
Published Fri, Jul 19 2024 8:15 PM UTC
In this article, we will analyze the recent market updates and their impact on Merck And Co Inc shares. We will interpret four articles to outline the facts and assess their influence on the company's stock performance. Additionally, we will provide a factual title for the article summarizing the findings. 1: Cancer Supportive Drugs Market Updates: Granulocyte Colony-Stimula...
|
| |
| U.S. |
|
 48.75 % |
of total Revenue |
| Non-US |
|
49.88 % |
of total Revenue |
| Corporate, Non-Segment |
|
1.38 % |
of total Revenue |
| Corporate, Non- U.S. |
|
0.14 % |
of total Revenue |
| Corporate, Non- Non-US |
|
1.24 % |
of total Revenue |
| Pharmaceutical |
|
89.42 % |
of total Revenue |
| Pharmaceutical U.S. |
|
45.92 % |
of total Revenue |
| Pharmaceutical Non-US |
|
43.5 % |
of total Revenue |
| Pharmaceutical Keytruda |
|
45.12 % |
of total Revenue |
| Pharmaceutical Keytruda U.S. |
|
27.38 % |
of total Revenue |
| Pharmaceutical Keytruda Non-US |
|
17.74 % |
of total Revenue |
| Pharmaceutical Alliance revenue - Lynparza |
|
1.97 % |
of total Revenue |
| Pharmaceutical Alliance revenue - Lynparza U.S. |
|
0.95 % |
of total Revenue |
| Pharmaceutical Alliance revenue - Lynparza Non-US |
|
1.02 % |
of total Revenue |
| Pharmaceutical Alliance revenue - Lenvima |
|
1.55 % |
of total Revenue |
| Pharmaceutical Alliance revenue - Lenvima U.S. |
|
1.1 % |
of total Revenue |
| Pharmaceutical Alliance revenue - Lenvima Non-US |
|
0.45 % |
of total Revenue |
| Pharmaceutical Welireg |
|
0.78 % |
of total Revenue |
| Pharmaceutical Welireg U.S. |
|
0.72 % |
of total Revenue |
| Pharmaceutical Welireg Non-US |
|
0.06 % |
of total Revenue |
| Pharmaceutical Alliance Revenue - Reblozyl |
|
0.56 % |
of total Revenue |
| Pharmaceutical Alliance Revenue - Reblozyl U.S. |
|
0.47 % |
of total Revenue |
| Pharmaceutical Alliance Revenue - Reblozyl Non-US |
|
0.09 % |
of total Revenue |
| Pharmaceutical Gardasil/Gardasil 9 |
|
15.38 % |
of total Revenue |
| Pharmaceutical Gardasil/Gardasil 9 U.S. |
|
3.33 % |
of total Revenue |
| Pharmaceutical Gardasil/Gardasil 9 Non-US |
|
12.05 % |
of total Revenue |
| Pharmaceutical ProQuad/M-M-R II/Varivax |
|
3.83 % |
of total Revenue |
| Pharmaceutical ProQuad/M-M-R II/Varivax U.S. |
|
3.04 % |
of total Revenue |
| Pharmaceutical ProQuad/M-M-R II/Varivax Non-US |
|
0.79 % |
of total Revenue |
| Pharmaceutical Vaxneuvance |
|
1.17 % |
of total Revenue |
| Pharmaceutical Vaxneuvance U.S. |
|
0.61 % |
of total Revenue |
| Pharmaceutical Vaxneuvance Non-US |
|
0.56 % |
of total Revenue |
| Pharmaceutical RotaTeq |
|
1.01 % |
of total Revenue |
| Pharmaceutical RotaTeq U.S. |
|
0.66 % |
of total Revenue |
| Pharmaceutical RotaTeq Non-US |
|
0.35 % |
of total Revenue |
| Pharmaceutical Pneumovax 23 |
|
0.37 % |
of total Revenue |
| Pharmaceutical Pneumovax 23 U.S. |
|
0.07 % |
of total Revenue |
| Pharmaceutical Pneumovax 23 Non-US |
|
0.3 % |
of total Revenue |
| Pharmaceutical Bridion |
|
2.82 % |
of total Revenue |
| Pharmaceutical Bridion U.S. |
|
2.18 % |
of total Revenue |
| Pharmaceutical Bridion Non-US |
|
0.65 % |
of total Revenue |
| Pharmaceutical Prevymis |
|
1.17 % |
of total Revenue |
| Pharmaceutical Prevymis U.S. |
|
0.56 % |
of total Revenue |
| Pharmaceutical Prevymis Non-US |
|
0.61 % |
of total Revenue |
| Pharmaceutical Dificid |
|
0.57 % |
of total Revenue |
| Pharmaceutical Dificid U.S. |
|
0.49 % |
of total Revenue |
| Pharmaceutical Dificid Non-US |
|
0.07 % |
of total Revenue |
| Pharmaceutical Zerbaxa |
|
0.38 % |
of total Revenue |
| Pharmaceutical Zerbaxa U.S. |
|
0.2 % |
of total Revenue |
| Pharmaceutical Zerbaxa Non-US |
|
0.17 % |
of total Revenue |
| Pharmaceutical Noxafil |
|
0.28 % |
of total Revenue |
| Pharmaceutical Noxafil Non-US |
|
0.27 % |
of total Revenue |
| Pharmaceutical Alliance revenue - Adempas/Verquvo |
|
0.66 % |
of total Revenue |
| Pharmaceutical Alliance revenue - Adempas/Verquvo U.S. |
|
0.61 % |
of total Revenue |
| Pharmaceutical Alliance revenue - Adempas/Verquvo Non-US |
|
0.05 % |
of total Revenue |
| Pharmaceutical Adempas |
|
0.45 % |
of total Revenue |
| Pharmaceutical Adempas Non-US |
|
0.45 % |
of total Revenue |
| Pharmaceutical Winrevair |
|
0.43 % |
of total Revenue |
| Pharmaceutical Winrevair U.S. |
|
0.43 % |
of total Revenue |
| Pharmaceutical Lagevrio |
|
0.68 % |
of total Revenue |
| Pharmaceutical Lagevrio U.S. |
|
0.09 % |
of total Revenue |
| Pharmaceutical Lagevrio Non-US |
|
0.59 % |
of total Revenue |
| Pharmaceutical Isentress/Isentress HD |
|
0.55 % |
of total Revenue |
| Pharmaceutical Isentress/Isentress HD U.S. |
|
0.27 % |
of total Revenue |
| Pharmaceutical Isentress/Isentress HD Non-US |
|
0.29 % |
of total Revenue |
| Pharmaceutical Delstrigo |
|
0.37 % |
of total Revenue |
| Pharmaceutical Delstrigo U.S. |
|
0.09 % |
of total Revenue |
| Pharmaceutical Delstrigo Non-US |
|
0.28 % |
of total Revenue |
| Pharmaceutical Pifeltro |
|
0.24 % |
of total Revenue |
| Pharmaceutical Pifeltro U.S. |
|
0.17 % |
of total Revenue |
| Pharmaceutical Pifeltro Non-US |
|
0.07 % |
of total Revenue |
| Pharmaceutical Belsomra |
|
0.33 % |
of total Revenue |
| Pharmaceutical Belsomra U.S. |
|
0.12 % |
of total Revenue |
| Pharmaceutical Belsomra Non-US |
|
0.21 % |
of total Revenue |
| Pharmaceutical Simponi |
|
1.07 % |
of total Revenue |
| Pharmaceutical Simponi Non-US |
|
1.07 % |
of total Revenue |
| Pharmaceutical Remicade |
|
0.22 % |
of total Revenue |
| Pharmaceutical Remicade Non-US |
|
0.22 % |
of total Revenue |
| Pharmaceutical Januvia |
|
2.51 % |
of total Revenue |
| Pharmaceutical Januvia U.S. |
|
1.1 % |
of total Revenue |
| Pharmaceutical Januvia Non-US |
|
1.41 % |
of total Revenue |
| Pharmaceutical Janumet |
|
1.39 % |
of total Revenue |
| Pharmaceutical Janumet U.S. |
|
0.11 % |
of total Revenue |
| Pharmaceutical Janumet Non-US |
|
1.29 % |
of total Revenue |
| Pharmaceutical Other pharmaceutical |
|
3.56 % |
of total Revenue |
| Pharmaceutical Other pharmaceutical U.S. |
|
1.18 % |
of total Revenue |
| Pharmaceutical Other pharmaceutical Non-US |
|
2.4 % |
of total Revenue |
| Animal Health |
|
9.2 % |
of total Revenue |
| Animal Health U.S. |
|
2.82 % |
of total Revenue |
| Animal Health Non-US |
|
6.37 % |
of total Revenue |
| Animal Health Livestock |
|
5.19 % |
of total Revenue |
| Animal Health Livestock U.S. |
|
1.04 % |
of total Revenue |
| Animal Health Livestock Non-US |
|
4.15 % |
of total Revenue |
| Animal Health Companion Animal |
|
4 % |
of total Revenue |
| Animal Health Companion Animal U.S. |
|
1.78 % |
of total Revenue |
| Animal Health Companion Animal Non-US |
|
2.22 % |
of total Revenue |
| United States |
|
48.88 % |
of total Revenue |
| Europe, Middle East and Africa |
|
21.82 % |
of total Revenue |
| China |
|
11.28 % |
of total Revenue |
| Latin America |
|
5.33 % |
of total Revenue |
| Japan |
|
4.26 % |
of total Revenue |
| Asia Pacific (other than China and Japan) |
|
4.64 % |
of total Revenue |
| Other |
|
3.8 % |
of total Revenue |
1.3%